Skip to main content

Table 1 Baseline characteristics

From: Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates

Baseline characteristic

Naïve group (n = 25)

Switch group (n = 11)

P

Age (years)

66.2 ± 1.6

75.4 ± 2.2

<0.05

Height (cm)

150.4 ± 1.5

145.4 ± 2.5

n.s

Weight (kg)

45.7 ± 1.6

43.0 ± 1.9

n.s

Spine BMD (g/cm2)

0.824 ± 0.03

0.889 ± 0.06

n.s

FN BMD (g/cm2)

0.60 ± 0.01

0.57 ± 0.03

n.s

TH BMD (g/cm2)

0.62 ± 0.01

0.62 ± 0.03

n.s

Total-PINP (ng/ml)

73.4 ± 5.5

36.8 ± 5.1

n.s

TRACP-5b (mU/dl)

426.2 ± 31.3

320.7 ± 21.0

<0.05

ucOC (ng/ml)

4.2 ± 0.5

2.3 ± 0.4

<0.05

BPs duration (years)

–

7.9 ± 0.4

–

BPs used

–

Alen 3, Ris 8

–

Previous fractures (%) a

28.0

81.8

<0.05

  1. Naïve group: treatment-naïve group; Switch group: transitioning from bisphosphonate group; BMD: bone mineral density; FN: femoral neck; TH: total hip; total-PINP: total-procollagen type I N-terminal propeptide; TRACP-5b: tartrate-resistant acid phosphatase-5b; ucOC: undercarboxylated osteocalcin; BPs: bisphosphonates; Alen: alendronate; Ris: risedronate
  2. aDefined as osteoporotic vertebral or nonvertebral fractures; assessment of vertebral fractures was performed for this study at baseline
  3. Data are presented as means ± standard deviation (SD). P values from Mann-Whitney U tests for continuous variables and Chi-squared tests for dichotomous variables